Bingliang Fang, M.D., Ph.D.
Department of Thoracic and Cardiovascular Surgery, Division of Surgery
About Dr. Fang
Dr. Bingliang Fang was born in Zhejiang, China. He received a Bachelor of Medicine from Zhejiang Medical University in 1982, and a Master of Medical Science from the Chinese Academy of Medical Sciences and the Peking Union Medical College in Beijing in 1985. In 1989, Dr. Fang received a Doctor of Medicine degree from Hamburg University in Germany, and then returned to the Chinese Academy of Medical Sciences and the Peking Union Medical College, where he was promoted to Assistant Professor.
1992, he joined the Department of Cell Biology of Baylor College of Medicine in Houston, as a Research Associate where he worked on gene therapy of genetic disorders. He joined The University of Texas M. D. Anderson Cancer Center, as an Assistant Professor and Assistant Biologist in the Department of Thoracic and Cardiovascular Surgery in 1995. Dr. Fang is a member of American Association for Cancer Research and American Chemical Society.
Present Title & Affiliation
Primary Appointment
Professor, Department of Thoracic and Cardiovascular Surgery - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1989 | Hamburg University Insitute of Human Genetics, Hamburg, DEU, PHD, Molecular Genetics |
| 1985 | Institute Basic Medicine Sci - China Acad Med Sci & Peking Union Med College, Bejing, CHN, MMS, Medicine Genetics |
| 1982 | Zhejiang Medical University, Zhejiang, CHN, BM, Medicine |
Honors & Awards
| 1993 | Post-Doctoral Fellow Award, Society of Chinese Geneticists in America |
| 1986 | Boehringer Ingelheim Fellowship |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res 7(8):1267-1279, 2019. e-Pub 2019. PMID: 31186248.
- Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J, Fang B. Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res 9(6):1201-1211, 2019. e-Pub 2019. PMID: 31285952.
- Pu X, Wu L, Su D, Mao W, Fang B. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 18(1):1082, 2018. e-Pub 2018. PMID: 30409126.
- Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B. Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. J Transl Med 16(1):328, 2018. e-Pub 2018. PMID: 30477533.
- Hou H, Zhu H, Zhao H, Yan W, Wang Y, Jiang M, Liu B, Liu D, Zhou N, Zhang C, Li P, Chang L, Guan Y, Wang Z, Zhang X, Li Z, Fang B, Zhang X. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile. Oncologist 23(9):1008-1015, 2018. e-Pub 2018. PMID: 29700208.
- Goltsov AA, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. Ann Thorac Surg 105(2):363-370, 2018. e-Pub 2017. PMID: 29223420.
- Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res 23(15):4212-4223, 2017. e-Pub 2017. PMID: 28348046.
- Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 161(5):1246-1254, 2017. e-Pub 2017. PMID: 28081955.
- Zhou W, Dai S, Zhu H, Song Z, Cai Y, Lee JB, Li Z, Hu X, Fang B, He C, Huang X. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer. Gene Ther 24(4):199-207, 2017. e-Pub 2017. PMID: 28075429.
- Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology 7(1):e1376156, 2017. e-Pub 2017. PMID: 29296537.
- Xiaobo C, Majidi M, Feng M, Shao R, Wang J, Zhao Y, Baladandayuthapani V, Song J, Fang B, Ji L, Mehran R, Roth JA. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Sci Rep 6:35741, 2016. e-Pub 2016. PMID: 27845352.
- White L, Wu S, Ma J, Fang B, Liang D. Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC-MS/MS: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 1033-1034:106-111, 2016. e-Pub 2016. PMID: 27541624.
- Yan X, Fang B. Harnessing plasma genotyping for precision therapy against lung cancer. J Thorac Dis 8(10):E1387-E1390, 2016. PMID: 27867637.
- Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan S, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang B. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 7(3):3548-58, 2016. e-Pub 2015. PMID: 26657290.
- Fang B. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochem Biophys Sin (Shanghai) 48(1):27-38, 2016. e-Pub 2015. PMID: 26350096.
- Wu S, Wang L, Huang X, Cao M, Hu J, Li H, Zhang H, Sun X, Meng QH, Hofstetter WL, Roth JA, Swisher SG, Fang B. Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380. Bioorg Med Chem 22(19):5234-40, 2014. e-Pub 2014. PMID: 25182964.
- Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells. J Natl Cancer Inst 106(9), 2014. e-Pub 2014. PMID: 25214559.
- Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, University of Texas MD Anderson Lung Cancer Collaborative Group [Fang B]. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15(1):e42-50, 2014. PMID: 24384493.
- Ji H, Wang J, Fang B, Fang X, Lu Z. a-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of ß-catenin transactivation. J Neurooncol 103(3):445-51, 2011. e-Pub 2010. PMID: 20872274.
- Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71(10):3658-68, 2011. e-Pub 2011. PMID: 21444672.
- Wu S, Wang L, Guo W, Liu X, Liu J, Wei X, Fang B. Analogues and Derivatives of Oncrasin-1, a Novel Inhibitor of the C-Terminal Domain of RNA Polymerase II and Their Antitumor Activities. J Med Chem 54(8):2668-79, 2011. e-Pub 2011. PMID: 21443218.
- Guo W, Wei X, Wu S, Wang L, Peng H, Wang J, Fang B. Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species. Eur J Pharmacol 649(1-3):51-8, 2010. e-Pub 2010. PMID: 20854805.
- Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 16(22):5522-8, 2010. e-Pub 2010. PMID: 20930042.
- Zhou Y, Hofstetter WL, He Y, Hu W, Pataer A, Wang L, Wang J, Zhou Y, Yu L, Fang B, Swisher SG. KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther 9(7):507-13, 2010. e-Pub 2010. PMID: 20215880.
- Ziauddin MF, Guo ZS, O'Malley ME, Austin F, Popovic PJ, Kavanagh MA, Li J, Sathaiah M, Thirunavukarasu P, Fang B, Lee YJ, Bartlett DL. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther 17(4):550-9, 2010. e-Pub 2010. PMID: 20182517.
- Wei X, Guo W, Wu S, Wang L, Huang P, Liu J, Fang B. Oxidative stress in NSC-741909-induced apoptosis of cancer cells. J Transl Med 8:37, 2010. e-Pub 2010. PMID: 20398386.
- Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 5(9):e13026, 2010. e-Pub 2010. PMID: 20885957.
- Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5(11):e14124, 2010. e-Pub 2010. PMID: 21124782.
- Meng J, Peng H, Dai B, Guo W, Wang L, Ji L, Minna JD, Chresta CM, Smith PD, Fang B, Roth JA. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 8(21):2073-80, 2009. e-Pub 2009. PMID: 19783898.
- Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, Aldape K, Lu Z. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 36(4):547-59, 2009. PMID: 19941816.
- Hu W, Hofstetter WL, Li H, Zhou Y, He Y, Pataer A, Wang L, Xie K, Swisher SG, Fang B. Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res 15(18):5688-95, 2009. e-Pub 2009. PMID: 19737957.
- Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem 284(25):16948-55, 2009. e-Pub 2009. PMID: 19414586.
- Guo W, Wu S, Wang L, Wang RY, Wei X, Liu J, Fang B. Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol Cancer Ther 8(2):441-8, 2009. e-Pub 2009. PMID: 19208825.
- Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 68(18):7403-8, 2008. PMID: 18794128.
- Hu W, Hofstetter W, Guo W, Li H, Pataer A, Peng HH, Guo ZS, Bartlett DL, Lin A, Swisher SG, Fang B. JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase. Cancer Gene Ther 15(9):616-24, 2008. e-Pub 2008. PMID: 18535619.
- Shamimi-Noori S, Yeow WS, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, Fang BL, Nguyen DM. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 15(6):356-70, 2008. e-Pub 2008. PMID: 18309355.
- Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 16(5):886-92, 2008. e-Pub 2008. PMID: 18388920.
- Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep 19(5):1071-7, 2008. PMID: 18425360.
- Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14(9):2813-23, 2008. PMID: 18451249.
- Zhou H, Wu S, Zhai S, Liu A, Sun Y, Li R, Zhang Y, Ekins S, Swaan PW, Fang B, Zhang B, Yan B. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem 51(5):1242-51, 2008. e-Pub 2008. PMID: 18257542.
- Hu W, Davis JJ, Zhu H, Dong F, Guo W, Ang J, Peng H, Guo ZS, Bartlett DL, Swisher SG, Fang B. Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther 6(11):1773-9, 2007. e-Pub 2007. PMID: 17986853.
- Zhu H, Zhu Y, Hu J, Hu W, Liao Y, Zhang J, Wang D, Huang X, Fang B, He C. Adenovirus-mediated small hairpin RNA targeting Bcl-XL as therapy for colon cancer. Int J Cancer 121(6):1366-72, 2007. PMID: 17534896.
- Deng WG, Nishizaki M, Fang B, Roth JA, Ji L. Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells. Biochem Biophys Res Commun 355(4):993-9, 2007. e-Pub 2007. PMID: 17328863.
- Hannay J, Davis JJ, Yu D, Liu J, Fang B, Pollock RE, Lev D. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther 14(8):671-81, 2007. e-Pub 2007. PMID: 17287860.
- Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G, Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Heymach JV, Fang B. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. e-Pub 2019. PMID: 31287557.
- Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng Q, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B. Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis. Cancer Res 79(1):125-132. e-Pub 2018. PMID: 30401714.
Invited Articles
- Dai B, Fang B, Roth JA. RNAi-Induced Synthetic Lethality in Cancer Therapy. Cancer Biol Ther 8(23):2314-6, 2009. e-Pub 2009. PMID: 19949302.
- Guo ZS, Li Q, Bartlett DL, Yang JY, Fang B. Gene transfer: the challenge of regulated gene expression. Trends Mol Med, 2008. PMID: 18692441.
- Guo W, Fang B. Potentiation of oncolytic virotherapy with armed shRNA. Cancer Biol Ther 8(1). e-Pub 2009. PMID: 19127117.
- Guo W, Fang B. Enhancing anti-cancer virotherapy with heat-shock protein-mediated immune response. Cancer Biol Ther 7(2):196-7. e-Pub 2008. PMID: 8347427.
Book Chapters
- Fang B, Roth JA. Tumour-suppressor gene therapy. In: Viral Therapy of Cancer. 1. John Wiley & Sons, Ltd: Rochester, MN, 229-239, 2008.
- Zhang L, Fang B. Oncogenes, Tumor Suppressor Genes and Apoptosis-Inducing Genes Utilized in Cancer Gene Therapy. In: Gene Therapy for Cancer: Cancer Drug Discovery and Development. 1st. Humana Press: Totowa, NJ, 173-184, 2007.
- Fang B, Roth JA. Adenovirus-mediated cancer gene therapy. In: Gene Therapy for Cancer: Cancer Drug Discovery and Development. 1st. Humana Press: Totowa, NJ, 3-22, 2007.
- Zhang L, Fang B. Gene therapy targeting receptor-mediated cell death to concers. In: Death Receptors in Cancer Therapy. Humana Press: Totowa, NJ, 339-354, 2005.
Grant & Contract Support
| Title: | Overcoming resistance to anti-EGFR therapy by drug repurposing |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | UT SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer - NSCLC Patient-Derived Xenografts for Accelerating Development of Anti-Lung Cancer Drugs |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Novel STAT3/RNA Polymerase II inhibitor and its predictive biomarker for lung cancer therapy |
| Funding Source: | Sister Institution Network Fund |
| Role: | Principal Investigator |
| Title: | University of Texas PDX Development and Trial Center - Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| Title: | UT SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer - Project 2: Epidemiologic Studies of Germline Polymorphisms in miRNA Pathways to Determine Their Role in Risk of Lung Cancer Development and Recurrence |
| Funding Source: | NIH/NCI |
| Role: | Co-Project Leader |
| Title: | University of Texas PDX Development and Trial Center - PDX Core |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| Title: | University of Texas PDX Development and Trial Center - Pilot Core |
| Funding Source: | NIH/NCI |
| Role: | Co-Core Leader |
| Title: | Novel Therapeutic Approaches for the Treatment of Cancer Using TUSC2 and Immunotherapy |
| Funding Source: | Genprex, Inc |
| Role: | Co-Investigator |
| Title: | UT SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer - Core A: Administrative Core |
| Funding Source: | NIH/NCI |
| Role: | Co-Core Director |
| Title: | Bay Area Team Against Resistance: Overcoming Resistance to Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | UT SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |